triazoles has been researched along with mk-7655 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aboklaish, AF; Brem, J; Jackson, DE; Langley, GW; Schofield, CJ; Tselepis, L; Tyrrell, JM; Walsh, TR; Widlake, E | 1 |
| Saral Sariyer, A | 1 |
2 other study(ies) available for triazoles and mk-7655
| Article | Year |
|---|---|
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cefepime; Drug Combinations; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Tazobactam; Triazoles | 2020 |
Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Microbial Sensitivity Tests; Molecular Docking Simulation; Triazoles | 2022 |